QLGN - Qualigen nabs additional U.S. patent for ALAN anticancer platform

Qualigen Therapeutics ([[QLGN]] +10.7%) announces that the United States Patent and Trademark Office has issued a patent related to its ALAN (Aptamer-Linked Anti-Nucleolin) technology.This patent issued protects the ALAN technology for use with cancer radiation therapy and for imaging tumors utilizing magnetic resonance imaging.The novel ALAN technology has several other potential applications, including its use as a monotherapy for the treatment of cancer and as a vehicle to deliver other anticancer compounds directly to tumors.The gold nanoparticle component of ALAN is believed to enhance radiation therapy with the potential to justify lower radiation exposure and, in turn, decrease side effects.ALAN is a DNA aptamer-based anticancer drug candidate that combines the DNA aptamer AS1411 with a gold nanoparticle to dramatically increase its potency. The Company plans to commence Phase 1 human trials with ALAN in 2021 in patients with acute myeloid leukemia, its lead indication.

For further details see:

Qualigen nabs additional U.S. patent for ALAN anticancer platform